HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on August 13 at 4:30 p.m. ET to review its financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The upcoming call provides an opportunity for investors and industry observers to gain insights into the company’s financial performance and strategic initiatives.
For more details, the full press release is available at https://ibn.fm/sqGLs. Additional information about HeartBeam and its cleared indications for use can be found at https://www.heartbeam.com/indications.
